• In 2020, direct sales saw record highs in sales, sellers and customers in the U.S.
• Growth across many categories within direct selling reflects broader consumer trends
• The Happy Co. is one of fastest-growing companies in the social-marketing, direct-selling industries

The resiliency of the direct-selling industry has never been more evident than during the global pandemic. Looking forward, the country’s economic situation remains fragile, but direct sales remains a bright spot on the horizon. A recent Direct Selling News article, titled “Four Reasons for Direct-Selling Optimism Post-Pandemic,” touts all that is right with the space (https://ibn.fm/sbexN) — a space in which Sharing Services Global (OTCQB: SHRG) and its direct-sales subsidiary, The Happy Co., is emerging as one of the fastest-growing companies. “Direct selling demonstrated its resilience in a challenging environment in the last year, achieving record highs in sales, sellers and customers in the U.S.,” stated the article. “As the U.S. economy continues its recovery from the pandemic, a continued rapidly evolving retail and labor market provides opportunities and challenges for direct selling, along with a few key reasons for long-term optimism.” According to the Direct Sales Association’s (“DSA”) 2021 Growth & Outlook Survey, direct-selling hit record sales last year of $40.1 billion, with 7.7 million direct sellers reaching more than 41.6 million customers throughout the year. “In the last year, direct selling was a source of in-demand products and services during a time when brick and mortar was largely shuttered and other parts of retail were slowed by significant supply chain issues,” the article reported. “You can see growth across many categories within direct selling, much of which is reflective of broader consumer trends.” As the title indicates, the article lists four major reasons that direct sales will remain a strong economic influence moving forward. First, based on several key indicators, the direct sales sector hasn’t slowed down this year. Second, growing numbers of Americans are looking for entrepreneurial, flexible earning opportunities. “Even with declining unemployment, there will likely be demand for diversified, supplemental income streams,” the article noted. “Direct selling continues to compare favorably.” Third, direct-selling companies are investing significant resources to transforming their companies virtually. Companies are working to integrate their e-commerce and mobile commerce efforts with the latest technology; they are also focusing on social selling, virtual events and faster payments. “These digital transformations likely put those companies in a stronger position to compete even as the brick and mortar reopens and retail competition ramps up,” the article observes. “The ability to combine the improved e-commerce/m-commerce/social-selling experience and its increased reach with the personal touch — that is a key differentiator for direct selling and can help drive sustained growth.” Finally, the article points to several post-pandemic retail trends that direct selling can capitalize on, including community; meeting customers with anything, anywhere, anytime; and in-person sales still representing the majority of retail for the near future. “Even though e-commerce grew at 32% last year and is expected to grow 18% this year, e-commerce only represents a fraction of overall retail,” the article stated. “The reopening of in-person shopping provides an enormous opportunity to meet customers where they are and combine the best of both worlds, leveraging the reach and convenience of online with the community, coaching, and personalization of in-person.” SHRG’s The Happy Co. is one of the fastest-growing companies in the social-marketing and direct-selling industries. The company has become the category creator for Happy Coffee and a recognized leader in natural nootropics. Sharing Services Global Corporation is a publicly traded diversified company dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies. The Sharing Services combined platform leverages the capabilities and expertise of various companies that market and sell products direct to the consumer. Its primary division includes Elevacity U.S. LLC, the parent company of the Happy Co. and a sales and marketing company based on utilization of independent contractors as the sales force. For more information, visit the company’s websites at www.SHRGInc.com and www.TheHappyCo.com. NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• SRAX reported their 3Q21 quarterly results on November 15, 2021
• The company reported 3Q21 revenues of $8.3 million, +219% YoY and +8% QoQ
• SRAX also reported that their 3Q21 EBITDA net loss narrowed to -$790k, with the company simultaneously revealing that their gross margin had widened to 78%
• SRAX’s investor intelligence platform, Sequire announced that their subscribers had swelled to 250 companies as of 3Q21, up from 225 companies at the end of the second quarter

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, recently published its third quarter 2021 quarterly results on Monday, November 15th (https://ibn.fm/vC1PH). SRAX reported third quarter revenues of $8.3 million, a figure which was up 219% year-over-year and 8% on a quarter-on-quarter basis. The company also seized on the opportunity to update their corporate revenue guidance, guiding for $10.1 million in Q4 revenues, whilst simultaneously re-affirming their fiscal year 2021 guidance and raising their target to $31.5 million. SRAX’s stellar third quarter continue a trend which has seen the company’s financial returns go from strength to strength over the past year. The company comfortably met their revised Q3 revenue guidance of $8.3 million, which had been upgraded following the release of Q2 results, whilst concurrently announcing Sequire’s 3Q21 bookings of $8.9 million, with Q4 set to rise to a record $12.5 million as of date. SRAX management revealed that they were projecting a further $4 million in Sequire bookings during the fourth quarter, a target which would drive the division’s total booked revenue in Q4 to $16.5 million and extend a run which has seen Sequire report twelve consecutive quarters of revenue growth. SRAX’s results also contained further indications of the company’s voyage towards sustainable profitability. The company reported third quarter gross margins of 78%, up from 67% in the same period last year, with their EBITDA loss declining to a mere -$790 thousand, narrowing from -$1.9 million in the third quarter of 2020. Christopher Miglino, Founder and CEO of SRAX elaborated on the results, “Our team continues to innovate on product, sales, and marketing; and this is translating into increased revenue. We will hit the high end of our 2021 guidance and are well positioned to close out 2021 strong, with an amazing 2022 on the horizon.” However, the positive earnings highlights were not limited to revenue growth alone. SRAX’s management have displayed impressive financial acuity, with cash at hand of over $34.2 million and receivables valued at $2.17mn due within 12 months (https://ibn.fm/K1yo0). With $14.3 million more liquid assets than total liabilities, the surplus suggests that the company – which boasts a net cash balance sheet, should be able to eliminate its debt without too much difficulty should it opt to do so. SRAX’s earnings announcement comes amidst a period of strong growth for the company. SRAX revealed that their Sequire investor intelligence platform had seen their number of subscribers swell to 250 public companies, a dramatic increase relative to the 225 companies on their platform in the second quarter and up from a mere 92 subscribers as of their Q3 2020 results. Moreover, and over the course of the past three months, SRAX have also launched their IR Website Builder, their SMS communication platform as well as VIRA, an IR-powered chatbot. SRAX and Sequire have also sought to provide additional value-added services to its legions of subscribers and followers with the company having successfully hosting the recent flagship and in-person LD Micro Event, an event which attracted over 750 in-person attendees and 12,000 virtual attendees. For more information, visit the company’s website at www.SRAX.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

Date: December 6-7, 2021 Venue: Boston, MA Reimbursement executives attempt to comply with stringent commercial and public payer standards as the diagnostic industry evolves and expands into ever more specialized areas of testing. Provisions and specific evidence required to ensure coverage are always evolving, but the technology appears to be progressing even faster, posing unique hurdles in showing product value and integrating innovative diagnostics into existing payment schemes. The Diagnostic Coverage & Reimbursement conference has brought together more than 1200 industry professionals over the last ten years to discuss crucial challenges affecting diagnostic technology pricing, allowing the industry to better integrate breakthrough tests into the healthcare sector.

Topics will include:

• A Look at the Evolving Contracting & Pricing from the Payer’s Perspective Landscape
• Evaluating Health Policy and Coverage Requirements from the Payer Perspective Panel Landscape
• Putting in Place Effective Appeals Process Planning and Execution
• Administration & Legislative Guidance in Forecasting Diagnostic Tests News and Updates

The Q1 Productions Diagnostic Coverage & Reimbursement Conference will provide attendees with targeted insight into the most pressing challenges in obtaining satisfactory payments, as well as a forward-focused look at rising industry trends and their implications for reimbursement efforts in the future editions. This conference provides an unrivaled chance for delegates to maximize methods to drive successful payment by sharing thoughts on diagnostics’ place within value-based frameworks and the possibilities for new income streams by engaging with pharmaceutical firms. Attendees will engage in peer-to-peer knowledge sharing while also benefiting from direct insight into payer perspectives on coverage and payment from a variety of perspectives, including small and big manufacturers, laboratories, and public and private payers.

Why is it important?

The attendees will gain firsthand insight into current solutions through a unique encounter with expert thinking leaders. You’ll learn about current subjects directly connected to your sector through lively panel discussions, case studies, and real-world proof. Your team has access to a platform where they may ask questions of experienced industry professionals. It’s a great opportunity to expand your knowledge and perceive things in a new light. You and your team will have access to insight and interaction. Collaborate with your peers to overcome common difficulties by drawing on their knowledge and expertise. This in-person event connects you with public and private payers for direct insight into policy creation and decision-making frameworks, allowing you to extend product coverage successfully. During Q&A after peer-led case studies and success stories, avoid errors, increase market access through lessons learned, and collaborate on solutions. In engaging discussion-based sessions, build ties with decision-makers as well as diagnostic industry peers. For more information, please visit https://ibn.fm/BcNaZ

• Investment banking firm The Maxim Group reiterates ‘buy’ rating on MCURF following the company’s updates on pivotal research and technology, including The Desire Project, manufacturing of synthetic ibogaine, and the iSTRYM platform
• MINDCURE is focused on developing psychedelic compounds to scale science-backed and evidentiary-based mental health therapy worldwide
• In July, MINDCURE filed for patents on two routes of full chemical synthesis, which initiated the production of Good Laboratory Practice (“GLP”) ibogaine, which will lead to the production of Good Manufacturing Practice (“GMP”) ibogaine to scale and manufacture a global supply of its synthetic ibogaine
• In addition to this pre-clinical trial, MINDCURE has completed the draft research protocol for The Desire Project, which incorporates MDMA with psychotherapy to help treat female sexual hypoactive disorder

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, recently provided updated information on the company’s studies and clinical trials, as well as its leading technology and the latest corporate operations. Through digital therapeutics (“DTx”), MINDCURE is focused on developing psychedelic compounds to scale science-backed and evidentiary-based mental health therapy worldwide. The company’s update shares significant milestones that have been reached this year for both operating arms, MINDCURE Research and MINDCURE Technology (https://ibn.fm/SAxmI). The research arm of MINDCURE offered several updates for 2021, including important milestones in its synthetic ibogaine manufacturing. In March 2021, the company initiated chemical synthesis routes to produce fully synthetic ibogaine. In July, MINDCURE filed for patents on two routes of full chemical synthesis, which initiated the production of Good Laboratory Practice (“GLP”) ibogaine, which will lead to the production of Good Manufacturing Practice (“GMP”) ibogaine, to scale and manufacture a global supply of its synthetic ibogaine. The company is currently on schedule to provide GLP ibogaine to its research partners by Q2 2022. The pre-clinical update from MINDCURE confirms that the company intends to send ibogaine material to its pre-clinical research partner. Initially, the product will be used for broad cardiac and neurological screens, with in-depth behavioral studies possible later on. Called MSYNTH-001, the program is expected to yield initial study results during the first quarter of 2022. In addition to this pre-clinical trial, MINDCURE has completed the draft research protocol for The Desire Project, a program that incorporates MDMA with psychotherapy to help treat female Hypoactive Sexual Desire Disorder (“HSDD”). MINDCURE expects to have a pre-IND meeting with the FDA during Q1 2022 and the commencement of Phase 2 by Q3 2022. “We are proud to report that MINDCURE’s core research programs are progressing rapidly, showcasing our disciplined commitment to advancing MINDCURE’s drug research and commercial production programs,” President and CEO of MINDCURE, Kelsey Ramsden, stated. “Concurrently, we maintain a focus on identifying opportunities to expand our drug development pipeline.” The company also reported on MINDCURE Technology operational segment milestones, more specifically on the iSTRYM digital platform’s progress. In August 2021, MINDCURE released the minimum viable product version of its digital therapeutics technology to partner clinics across North America, with great success – the company has so far partnered with 20 ketamine clinics in nine different states in the U.S. and three Canadian provinces. Continuing to work toward becoming a leader in the distribution of high-quality therapy protocols through iSTRYM, the company plans to commence full commercial deployment of its digital therapeutics platform to partner clinics early next year, while also planning to expand to Europe and the UK by Q4 2022. Corporate-wise, the company announced that it granted 30,000 stock options to certain employees and that it engaged the services of Sandstone Media LLC for comprehensive marketing and media strategy and services, including product and brand awareness, content creation, social media, advertising, and more. A day after MINDCURE released its update, leading investment banking and wealth management firm The Maxim Group reiterated a ‘buy’ rating for the company, noting the progress achieved across its research and technology programs and pipeline, from iSTRYM to ibogaine and The Desire Project. In its analysis report, The Maxim Group underlined that it is key for the company in 2021 to continue with the block and tackle approach. This approach puts the company in the best position in the evolving psychedelic-based medicine space, the report says. According to the investment bank, even if share value dropped in 2021, all the pieces should fall into place for MINDCURE shares to do well in 2022. For more information, visit the company’s website at www.MindCure.com. NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF Forward-Looking Information Certain information presented in this article may constitute “forward-looking information” within the meaning of applicable securities laws regarding MINDCURE and its business. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases. Forward-looking information is based on a number of key expectations and assumptions made by management of MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; the Company will develop its products as expected and that they will attain the outcomes anticipated; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that strategic partnerships entered by the Company will create the opportunities and outcomes anticipated; that MINDCURE will advance wellness worldwide; that trading on the OTCQX will attract additional investment and provide additional liquidity for shareholders. Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information inherently entails known and unknown risks and uncertainties about the future and actual results and involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: successful clinical studies relating to ibogaine and the Desire Project, successfully synthesizing and manufacturing of ibogaine, the successful development, integration and deployment of iSTRYM, the successful development of appropriate Ketamine protocols, and acquiring adequate protection of any IP developed. Although MINDCURE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those described in forward-looking information presented, there may be other factors that cause results, performance or achievements to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements as no forward-looking information can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and MINDCURE does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release. For further information MINDCURE Investor Relations investors@mindcure.com 1-888-593-8995 Media Inquiries Annie Graf / Kristin Cwalinski KCSA Strategic Communications

• The NCIA will host the 7th Annual Cannabis Business Summit & Expo on December 15-17, 2021, in San Francisco
• This year’s event will feature BLOOM: A Brands Experience, designed to provide attendees with the ability to see, touch, and smell a variety of cannabis products on the expo floor
• In addition to Bloom, the conference will also feature two unique offsite tours, including a visit to the Dark Heart Nursery, as well as a unique cannabis-infused San Francisco city cruise

NCIA’s 7th Annual Cannabis Business Summit & Expo takes place at San Francisco’s Moscone Center from December 15-17, 2021. Hosted by the National Cannabis Industry Association (“NCIA”), the oldest and most influential trade association representing the legal cannabis business, the event will showcase over 125 speakers, more than 80 individual education sessions, and hundreds of exhibitors representing the full cannabis ecosystem. For the first time this year, #CannaBizSummit will debut BLOOM: A Brands Experience. A “show within a show,” BLOOM is an experiential showcase wherein licensed retailers, distributors, infused product manufacturers, and consumer enthusiasts, will have the opportunity to see, touch, and smell products from dozens of brands. The unique sensory experience will include flower, pre-roll, vapor, oil, edibles, and additional product categories. This, in addition to the ability to shop and compare the latest technology, products, and services, watch live demos, and evaluate product offerings side-by-side from hundreds of expo exhibitors. What’s more, the conference will also feature hundreds of engaging speakers, hand-selected for their expert knowledge, who will share secrets of the trade to help attendees future-proof their respective cannabis businesses – even in the backdrop of economic and environmental change. Throughout the show, attendees will be able to reconnect with colleagues and form new business connections during networking events, and even listen to podcasts on a live Podcast Stage. In addition to event’s core offerings, this year’s #CannaBizSummit offers a pair of experiential offsite tours, including a destination trip to Dark Heart Nursery and a cannabis-infused San Francisco city cruise. Please note that additional fees and registration are required for offsite tours. For more information about the Cannabis Business Summit & Expo, including event registration, visit https://cannabisbusinesssummit.com

• FingerMotion released results from the annual meeting held on November 22, 2021
• It announced the re-appointment of executive officers and its Board of Directors
• It also reported on the appointment of an independent accounting firm

FingerMotion (OTCQX: FNGR) held its annual meeting of stockholders on November 22, 2021. Among the issues covered included the election of specific figures into the company’s Board of Directors, coupled with the approval of the FNGR 2021 stock incentive plan and executive compensation. The company just announced that various matters were duly ratified and have since been implemented by its Board. They included:

• The election of Hsien Loong Wong, Leong Yew Poh, Michael Chan, and Ng Eng Ho into FingerMotion’s Board of Directors
• The re-appointment of Martin Shen as President and Chief Executive Officer and Yew Hon Lee as the Chief Financial Officer, Secretary, and Treasurer of the company
• The selection of Centurion ZD CPA & Co. as FingerMotion’s independent registered public accounting firm
• The sanction of the company’s 2021 Stock Incentive Plan
• The endorsement of the company’s executive compensation
• The acceptance of the frequency of stockholder votes on the company’s executive compensation to be presented to stockholders annually (https://ibn.fm/DwZF0)

These strategic appointments and approvals are geared towards pushing the company forward as it develops supplementary value-added technologies to market to its users. Additionally, they are laying down the foundation in what is expected to be a successful 2022 financial year. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• Flora Growth recently entered into a licensing agreement to produce and distribute Tonino Lamborghini-branded cannabis beverages across North America and Colombia, with an initial focus on the U.S. market
• The company will produce the product line using molecular tagging and authentication technology that will guarantee product verification and allay concerns of counterfeit products
• Through the licensing agreement, Flora has entered into the cannabis beverages market amid increasing demand for CBD-based products
• The recent agreement follows a November 15 announcement that FLGC had completed the acquisition of Vessel Brand Inc., an industry leader in luxury cannabis consumer technology

Internationally focused cannabis brand builder Flora Growth (NASDAQ: FLGC) recently signed a licensing agreement with Tonino Lamborghini, a luxury brand operating in the high-end designer products, hotel, beverage, and real estate segments. Under the terms of the partnership announced November 29, Flora Growth will produce and distribute Tonino Lamborghini-branded cannabis beverages across North America and Colombia (https://ibn.fm/rDa9T). The Tonino Lamborghini product line, which will be produced in Florida for initial sale in US states where cannabidiol (“CBD”) ingestible are legal, will contain CBD and other premium cannabinoids, including cannabigerol (“CBG”). In addition, Flora will produce the product line using Applied DNA Sciences, Inc.’s (NASDAQ: APDN) molecular tagging and authentication technology, ensuring product verification and substantially reducing concerns of any counterfeit products or illicit market across North America or Colombia. Notably, this practice dovetails with the new age of cannabis consumer packaged goods (“CPG”). Under the licensing deal, Flora will retain the right of first refusal to produce and distribute any CBD or CBG products around the world under the Tonino Lamborghini brand. Tonino Lamborghini, the eponymous company’s founder, launched a line of designer beverage products in the mid-90s, becoming the first entrepreneur to achieve this feat. Since then, the company has been driven by the mission to propagate the brand’s intrinsic energy through a selection of drinks. Presently, Tonino Lamborghini produces an exclusive line of signature drinks, including energy drinks, espresso coffee in three different blends, soluble chocolates in eight flavors, vodka, and wines (https://ibn.fm/CtrXa). With CBD- or tetrahydrocannabinol (“THC”)-infused alcoholic drinks currently illegal in the United States, Flora Growth plans to concentrate on Tonino Lamborghini’s non-alcoholic beverages. The company says that infusing coffee, one of the most popular beverage segments globally, with cannabinoids, for example, will serve as a strong differentiator for the product line, beyond its connection to the luxury brand, particularly with the growing demand for CBD-based products. According to an analysis by BDS Analytics, CBD now represents a booming market in the United States, where, buoyed by the emergence of marijuana dispensaries, CBD sales are projected to reach $20 billion by 2024, up from $1.9 billion in 2018. This figure will translate to a global market share of 44%, considering BDS forecasts that the global CBD market will reach $45 billion in 2024 (https://ibn.fm/Z5cQT). Further, BDS notes that as the popularity of CBD has gathered momentum, piquing the interest of even more consumers, so too has it persuaded the established corporations to create CBD products. Flora Growth’s recent partnership with Tonino Lamborghini is a testament to this statement. “We are excited to partner with such a well-known luxury brand as Tonino Lamborghini, which already boasts a very successful line of beverages and aligns with Flora’s brand portfolio of high-end products,” stated Flora Growth CEO Luis Merchan. “This partnership is yet another step in the execution of Flora’s strategic plan to build a world-class house of brands and is also a major component of our sales and distribution strategy in the lucrative US market.” The company’s recent licensing agreement follows on the heels of the acquisition of Vessel Brand Inc. (“Vessel”), a Carlsbad, California-headquartered industry leader in luxury cannabis consumer technology. Boasting a proven go-to-market strategy for direct-to-consumer sales for the US and global cannabis markets that has resulted in rapid growth since inception in 2018, Vessel will serve as a critical component of FLGC’s North American cannabis strategy (https://ibn.fm/MSIxx). Flora Growth, which operates one of the largest outdoor cultivation facilities in the world, leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Previously, through its Kasa Wholefoods division, the company only produced non-cannabis drinks from responsibly sourced exotic Amazonian fruits. The recent partnership, therefore, marks Flora Growth’s entry into the cannabis beverages market. For more information, visit the company’s website at www.FloraGrowth.ca. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• PlantX seeks to redefine the plant-based community through e-commerce, content sharing, and community-building efforts
• With over 5,000 plant-based products, the company also promises to be the one-stop-shop for everything plant-based
• It is leveraging the internet and technology to bring its products and services closer to customers
• By doing so, it is laying down the standard operating procedures for achieving success as a plant-based e-commerce enterprise

As of 2019, the plant-based food and beverage market in North America was valued at $14.08 billion (https://ibn.fm/XehMr). Globally, it is projected that by 2027, this industry will be valued at $74.2 billion, representing a CAGR of 11.9% over the forecast period (2020-2027) (https://ibn.fm/owfWJ). This growth will be attributed to the increasing incidence of intolerance for animal proteins, a growing vegan population, the nutritional benefits offered by plant-based food, along with venture investments in plant-based food. This opportunity has seen many entrants into this space, each trying to carve out a niche and a market share for themselves. Globally, over 800 different brands and companies either focus on plant-based foods in place of animal products or have a business unit dedicated to such products (https://ibn.fm/9qd8s). In the North American market, one enterprise that is at the forefront of them all is PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) PlantX’s main aim is to redefine the plant-based community. It plans to achieve this through various avenues, including e-commerce, content sharing, and community-building efforts. This company is not all about making sales. Instead, it is about growing the plant-based community, educating the masses, and creating an environment where each member can thrive, grow and learn something new. PlantX promises to be the one-stop shop for everything plant-based. The company is banking on technology and the internet to bring its products and services even closer to the customers. So far, for the North American market, PlantX has over 5,000 plant-based products, with the list constantly growing as it acquires new brands and continues to develop new products. The company’s strategic locations also facilitate same-day delivery on plant-based products, ultimately improving the overall customer experience, and facilitating a comfortable plant-based lifestyle. PlantX’s recent addition of a subscription service that caters to recurring services is also a testament to its commitment to further strengthening its e-commerce model while also helping to overcome potential barriers to a healthy lifestyle such as time and cost (https://ibn.fm/yoVCD). PlantX is laying down the standard operating procedures to succeed as a plant-based e-commerce enterprise by executing its plans and achieving its objectives. Its first-mover advantage has earned it a rightful position as the leader in this space. So far, PlantX has made significant achievements as it continues to innovate, improve its products and services and find new ways to improve the plant-based community. Overall, this is helping to push the brand even further while also advancing the plant-based industry as a whole. For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://investor.plantx.com/ and view PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

• Groundwork exploration kicked off in August, led by Orix Geosciences
• The survey revealed multiple areas of high merit and potential mineralization
• This complements a sediment sampling conducted back in 2001 by the Ontario Geological Survey
• With these results, StraightUp can now execute its right to acquire 100% interest in the property

In early 2021, StraightUp Resources (CSE: ST) (OTCQB: STUPF) acquired an option to purchase the Ferdinand Gold Property in Ontario and set out to explore the property for potential mineralization (https://ibn.fm/o1XoL). Groundwork exploration kicked off in the month of August, spearheaded by Orix Geosciences. On November 29, 2021, the company announced having completed all of 2021 ground exploration on the property. The study, which involved heliborne magnetic surveys, revealed multiple areas of high merit and potential mineralization, a significant achievement for the company (https://ibn.fm/Wh23o). “We now have confirmation of D2 folding and ultramafic rocks, together considered to be a primary control for high-grade gold mineralization in this region, especially the Great Bear Resources Dixie Lake Gold Project,” noted Mark Brezer, the President and Chief Executive Officer (“CEO”) of StraightUp. “This study represents a transformation of the Ferdinand Gold Project and we couldn’t be more excited about the road ahead in this unexplored and unappreciated section of the infamous Uchi subprovince,” he added. This just-concluded survey complements a sediment sampling conducted by the Ontario Geological Survey back in 2001. This study revealed distinct clustering of lake sediment samples anomalous in specific minerals that further allowed for new targets for potential mineralization to be identified. With these results, StraightUp now can execute its right to acquire 100% interest in the property, which comprises 17 mining claims comprising 354 cells spread across 7,143 hectares. The property is located within the south Uchi greenstone belt, 13 km northwest of Slate Falls town and 120 km east of Red Lake, Ontario. The conclusion of this exploration marks a significant milestone for StraightUp, particularly as it aligns with its commitment to mineral exploration and the acquisition of mineral property assets in North America. The company is determined to continue maximizing shareholder wealth as it makes discoveries at projects with great potential within the region. StraightUp also announced the closure of the 4th tranche of financing for a sum of $100,000. The money will be raised by issuing 150,000 warrants and 500,000 common shares, exercisable at $0.30 until November 15, 2023. The proceeds from the offering will fund exploration projects and property expenditures, as well as working capital. All securities issued will be subject to a 4-month hold period expiring March 16, 2022. For more information, visit the company’s website at www.StraightUpResources.com. NOTE TO INVESTORS: The latest news and updates relating to STUPF are available in the company’s newsroom at https://ibn.fm/STUPF

• Avricore Health is a point of care pharmacy services developer that is providing lab-quality testing for select health conditions at pharmacies in Canada
• Avricore’s trademarked HealthTab(TM) platform networks patients, pharmaceutical professionals and other medical providers with a patient-privacy respecting solution that helps patients monitor their conditions at local community stores without the necessity of busy doctors’ offices scheduling
• In addition to the kidney-function monitoring solution announced just recently, HealthTab is currently outfitted to provide lab results for evaluating diabetes, heart disease, COVID, RSV, and other viral exposures
• Avricore’s pilot HealthTab rollout includes sites in eastern Canada’s Ontario province and western Canada’s British Columbia, where it is gathering information that will help its plans for a broader HealthTab rollout in Canada and other nations
• Avricore anticipates strong growth of the HealthTab network in Canada, and abroad, in 2023

Point of care health testing technology innovator Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) has rolled out its trademarked HealthTab platform in select Ontario and British Columbia Shoppers Drug Mart network pharmacies and continues to add lab-accurate test functionality to its kiosks, most recently announcing a solution for monitoring kidney function. Avricore signed a non-exclusive distribution agreement in Canada with multinational medical devices and health care company Abbott Laboratories to distribute Abbott’s handheld blood chemistry analyzer, i-STAT Alinity, through Avricore’s Canadian outlets, announcing Nov. 23 that the device will help patients monitor their creatinine levels. “Understanding renal function in patients at risk from or already living with chronic disease is critical,” Avricore Health CEO Hector Bremner stated (https://ibn.fm/xhjGU). “With i-STAT Alinity and its associated test for creatinine, healthcare professionals can obtain results in approximately two minutes to detect elevated levels of creatinine that are associated with abnormal renal function.” HealthTab is a communications network solution that allows pharmacies to provide patients testing services at neighborhood stores under the direction of trained professionals, thereby granting patients localized options for monitoring their health conditions without the necessity of visits to busy doctor clinics to get lab work done. HealthTab draws real-time data from blood samples and other fluids and communicates it to patients and medical care providers, respecting patient privacy concerns as well as medical provider concerns about the accuracy of the lab tests. Avricore has established an agreement with Abbott to provide the POC testing at Avricore’s partner pharmacies using Abbott’s trademarked ID Now kiosks. Agreements in the pilot stage allow for testing for markers related to conditions such as diabetes, heart disease (https://ibn.fm/5hEOz) and viruses such as COVID’s SARS-CoV-2, RSV, influenza A and B, and strep (https://ibn.fm/Xdj0d) empowering patients who want to take a greater role in managing their conditions. Avricore’s purpose is to likewise empower community pharmacies, particularly those in Canada whose revenues were impacted by the Pan-Canadian Select Molecule Price Initiative for Generic Drugs in 2018 that reduced retail margins in reimbursements. Avricore will build on its pilot program operations, using feedback from pharmacists and patients to support a broader launch into several pharmacy chains throughout Canada, the United States and Europe. The company anticipates establishing its POC health testing kiosks in 600 locations by the end of 2023 (https://ibn.fm/5zVGD). “We’ve demonstrated a unique resilience by remaining focused on our goal of creating the world’s largest rapid testing network in pharmacy,” Bremner stated earlier this year (https://ibn.fm/ivPKX). “We are well on our way to making actionable health information more accessible for everyone and dramatically expanding our network in the coming months.” For more information, visit the company’s website at www.AvricoreHealth.com. NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF